Clinical Investigation: Editorial

Jennifer Stewart

I am pleased to mention that during the year 2019, all issues of volume 9 were published online well within the time and the print issues were also brought out and dispatched within 30 days of publishing the issue online. Clinical Investigation (OACLI) caters to the clinical drug development and methodology, facilitating the rapid publication of research outcomes on new drug data from human studies. The journal includes topics like safety and effectiveness of medications, devices, diagnostic products and treatment regimens intended for human use. Also, the journal publishes an expert analysis of ongoing Phase I–IV trials and perspectives on how to run future trials. The journal offers thoroughly reviewed original research as research articles, review articles, Clinical Trial Protocols, Clinical Trial Perspectives, Clinical Trial Outcomes, Clinical Trial Reports, Clinical Trial Methodologies, Clinical Trial phase I-IV findings, Commentaries on Clinical trials, case studies, commentaries, Short Communication, and Letters to the Editors in the areas not limited to Regulations and guidelines on drug development and delivery, legal and ethical issues of clinical trials, issues of testing of novel drugs, new medical procedure, new medical devices, etc. The Impact factor of OACLI for the year 2018 was 2.75*, Indexing and abstracting coverage of Publons, Google Scholar, Journal TOCs, Genamics Journal Seek, RefSeek, OCLC-WorldCat and the PubMed NLM ID of our journal is- 101554582.